partnering

News

Sanofi pays $180m for rights to Kali autoimmune drug

Sanofi has licensed rights to Kali's trispecific T-cell engager KT501, in trials for rheumatoid arthritis, in a deal valued at nearly $1.2bn.

News

Novo Nordisk beefs up in oral obesity drugs with Vivtex deal

Novo Nordisk is leaving no stone unturned in its bid to maintain its position in weight-loss therapies as it signs a $2.1bn alliance with Vivtex.

News

Takeda signs $1.7bn AI alliance with Iambic

Iambic bags another pharma partner, Takeda, which plans to use its AI platform to find drugs for cancer, gastrointestinal, and inflammatory disorders.

News

Lilly strikes $8.8bn-plus alliance with China's Innovent

Eli Lilly has deepened its ties with Chinese biopharma company Innovent Biologics, signing a seventh R&D with a $350m upfront payment.

News

Grail multi-cancer test taps into Hims & Hers network

Grail has teamed up with telehealth company Hims & Hers to boost access to its recently filed Galleri blood test for cancer screening.

News

GSK departs Wave's AATD programme

Wave Life Sciences has lost GSK as the partner for its alpha-1 antitrypsin deficiency drug, but other partnered RNA-editing programmes remain active.

Sanofi pays $180m for rights to Kali autoimmune drug

Novo Nordisk beefs up in oral obesity drugs with Vivtex deal

Takeda signs $1.7bn AI alliance with Iambic

Lilly strikes $8.8bn-plus alliance with China's Innovent

Grail multi-cancer test taps into Hims & Hers network

GSK departs Wave's AATD programme

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

partnering

Editor's Picks